Adamis target doubled by Maxim

Maxim doubles Adamis price target to $10, sees partnership coming for Symjepi. As previously reported, Maxim analyst Jason McCarthy raised his price target on Adamis Pharmaceuticals to $10 from $5, stating that he sees growing revenue in the compounding business continuing to partially offset cash burn and expects that a partnership for Symjepi will come with an upfront payment that could extend the company’s cash runway. While the billion-dollar anaphylaxis market is “ready for a lower-cost, high-quality alternative like Symjepi,” there is also additional upside in the pipeline not yet factored into the stock, said McCarthy, who keeps a Buy rating on Adamis.

https://bit.ly/2rEzXSG